Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by 1wascallywabbiton Mar 27, 2017 1:36pm
303 Views
Post# 26036595

RE:BCG Shortage Again

RE:BCG Shortage AgainYep. BCG very toxic, and about 17% success rate and major side effects. 
MCNA not toxic at all and 25-35% desease free survival 1-3 years. And the FDA squashes it as it was a small Cdn Biotech that would provide competition to USA based company that supply the present treatment, even though doctors and scientists on the panel wanted it approved. Go figure. Like was said here, don't count your chickens - the FDA can be brutal - wolves in sheeps clothing that come across as being so in favour of your drug and even encouraging you to submit with limited data, and then BAM! Killed the company, investors and most tragically the patients who so badly needed MCNA to be Approved. Hopefully PLI has a Partner lined up to get this thru the door soon.
Bullboard Posts